Yesterday, medical-device maker FoxHollow Technologies
FoxHollow's product revenue was ultimately unable to overcome a combination of charges relating to stock-based compensation, lease terminations, and other SG&A expenses. All those factors drove the company to report a net loss of $0.18 per share, versus a net loss of $0.01 in the prior-year quarter.
Despite several positive recent developments, FoxHollow still has a long road ahead. Management's 2007 guidance for EPS in the range of $0.00-$0.20, and revenues in the range of $205 million-$215 million, lags analysts' expectations for EPS of $0.48 on $213 million in revenue.
Last month, FoxHollow entered into a collaborative agreement with eV3
Aside from an accumulated deficit, FoxHollow maintains a very strong balance sheet, with no long-term debt and an ample amount of cash. Product revenues increased by more than 50% for the company's full-year results, and FoxHollow predicts another year of double-digit sales growth. FoxHollow's SilverHawk is immensely profitable, targeting a large PAD market; the condition is estimated to afflict approximately 12 million people nationwide. Even megacap pharmaceutical Sanofi-Aventis
For high-tech companies with more promising prospects for explosive growth, try a free 30-day subscription to David Gardner's Motley Fool Rule Breakers.
Fool contributor Billy Fisher does not own shares of any of the companies mentioned.
More from The Motley Fool
You Need to Hear the SEC's Warning on Cryptocurrencies and ICOs
Before you invest in the next hot ICO, here's what you need to know.
Americans Say It Takes $2.4 Million to Be Wealthy. Here's How to Get There in Time for Retirement
Think you'll never be a millionaire? It's easier than you might expect.
Better Buy: Amazon.com, Inc. vs. Google
We pit these two market titans against each other to see which is the best investment today.